RESUMO
ASP2397 is a new compound with a novel and as-yet-unknown target different from that of licensed antifungal agents. It has activity against Aspergillus and Candida glabrata. We compared its in vitro activity against wild-type and azole-resistant A. fumigatus and A. terreus isolates with that of amphotericin B, itraconazole, posaconazole, and voriconazole. Thirty-four isolates, including 4 wild-type A. fumigatus isolates, 24 A. fumigatus isolates with alterations in CYP51A TR/L98H (5 isolates), M220 (9 isolates), G54 (9 isolates), and HapE (1 isolate), and A. terreus isolates (2 wild-type isolates and 1 isolate with an M217I CYP51A alteration), were analyzed. EUCAST E.Def 9.2 and CLSI M38-A2 MIC susceptibility testing was performed. ASP2397 MIC50 values (in milligrams per liter, with MIC ranges in parentheses) determined by EUCAST and CLSI were 0.5 (0.25 to 1) and 0.25 (0.06 to 0.25) against A. fumigatus CYP51A wild-type isolates and were similarly 0.5 (0.125 to >4) and 0.125 (0.06 to >4) against azole-resistant A. fumigatus isolates, respectively. These values were comparable to those for amphotericin B, which were 0.25 (0.125 to 0.5) and 0.25 (0.125 to 0.25) against wild-type isolates and 0.25 (0.125 to 1) and 0.25 (0.125 to 1) against isolates with azole resistance mechanisms, respectively. In contrast, MICs for the azole compounds were elevated and highest for itraconazole: >4 (1 to >4) and 4 (0.5 to >4) against isolates with azole resistance mechanisms compared to 0.125 (0.125 to 0.25) and 0.125 (0.06 to 0.25) against wild-type isolates, respectively. ASP2397 was active against A. terreus CYP51A wild-type isolates (MIC 0.5 to 1), whereas MICs of both azole and ASP2397 were elevated for the mutant isolate. ASP2397 displayed in vitro activity against A. fumigatus and A. terreus isolates which was independent of the presence or absence of azole target gene resistance mutations in A. fumigatus. The findings are promising at a time when azole-resistant A. fumigatus is emerging globally.
Assuntos
Antifúngicos/farmacologia , Aspergillus fumigatus/efeitos dos fármacos , Aspergillus/efeitos dos fármacos , Complexos de Coordenação/farmacologia , Sistema Enzimático do Citocromo P-450/genética , Farmacorresistência Fúngica/efeitos dos fármacos , Proteínas Fúngicas/genética , Peptídeos Cíclicos/farmacologia , Substituição de Aminoácidos , Anfotericina B/farmacologia , Aspergilose/microbiologia , Aspergillus/enzimologia , Aspergillus/genética , Aspergillus/isolamento & purificação , Aspergillus fumigatus/enzimologia , Aspergillus fumigatus/genética , Aspergillus fumigatus/isolamento & purificação , Azóis/farmacologia , Sistema Enzimático do Citocromo P-450/metabolismo , Farmacorresistência Fúngica/genética , Proteínas Fúngicas/metabolismo , Expressão Gênica , Humanos , Itraconazol/farmacologia , Testes de Sensibilidade Microbiana , Mutação , Triazóis/farmacologia , Voriconazol/farmacologiaRESUMO
The in vitro activity of isavuconazole against Mucorales isolates measured by EUCAST E.Def 9.2 and CLSI M38-A2 methodologies was investigated in comparison with those of amphotericin B, posaconazole, and voriconazole. Seventy-two isolates were included: 12 of Lichtheimia corymbifera, 5 of Lichtheimia ramosa, 5 of group I and 9 of group II of Mucor circinelloides, 9 of Rhizomucor pusillus, 26 of Rhizopus microsporus, and 6 of Rhizopus oryzae. Species identification was confirmed by internal transcribed spacer (ITS) sequencing. EUCAST MICs were read on day 1 (EUCAST-d1) and day 2 (EUCAST-d2), and CLSI MICs were read on day 2 (CLSI-d2). Isavuconazole MIC50s (range) (mg/liter) by EUCAST-d1, CLSI-d2, and EUCAST-d2 were 1 (0.125 to 16), 1 (0.125 to 2), and 4 (0.5 to >16), respectively, across all isolates. The similar values for comparator drugs were as follows: posaconazole, 0.25 (≤ 0.03 to >16), 0.25 (0.06 to >16), and 1 (0.06 to >16); amphotericin, 0.06 (≤ 0.03 to 0.5), 0.06 (≤ 0.03 to 0.25), and 0.125 (≤ 0.03 to 1); voriconazole, 16 (2 to >16), 8 (1 to >16), and >16 (8 to >16), respectively. Isavuconazole activity varied by species: Lichtheimia corymbifera, 1 (0.5 to 2), 1 (1 to 2), and 2 (1 to 4); Lichtheimia ramosa, 0.25 (0.125 to 0.5), 1 (0.5 to 2), and 2 (0.5 to 4); Rhizomucor pusillus, 0.5 (0.5 to 1), 1 (0.125 to 1), and 2 (1 to 2); Rhizopus microsporus, 1 (0.5 to 4), 0.5 (0.125 to 1), and 4 (1 to 8); and Rhizopus oryzae, 1 (0.5 to 4), 1 (0.125 to 2), and 4 (0.5 to 8), respectively, were more susceptible than Mucor circinelloides: group I, 8 (4 to 8), 4 (2 to 4), and 16 (2 to 16), respectively, and group II, 8 (1 to 16), 8 (1 to 8), and 16 (4 to >16), respectively. This was also observed for posaconazole. The essential agreement was best between EUCAST-d1 and CLSI-d2 (75% to 83%). Isavuconazole displayed in vitro activity against Mucorales isolates with the exception of Mucor circinelloides. The MICs were in general 1 to 3 steps higher than those for posaconazole. However, in the clinical setting this may be compensated for by the higher exposure at standard dosing.
Assuntos
Antifúngicos/farmacologia , Mucorales/efeitos dos fármacos , Mucormicose/microbiologia , Nitrilas/farmacologia , Piridinas/farmacologia , Triazóis/farmacologia , Fungos/efeitos dos fármacos , Humanos , Testes de Sensibilidade Microbiana , Especificidade da EspécieRESUMO
OBJECTIVES: The objective of this study was to characterize the underlying molecular mechanisms in consecutive clinical Candida albicans isolates from a single patient displaying stepwise-acquired multidrug resistance. METHODS: Nine clinical isolates (P-1 to P-9) were susceptibility tested by EUCAST EDef 7.2 and Etest. P-4, P-5, P-7, P-8 and P-9 were available for further studies. Relatedness was evaluated by MLST. Additional genes were analysed by sequencing (including FKS1, ERG11, ERG2 and TAC1) and gene expression by quantitative PCR (CDR1, CDR2 and ERG11). UV-spectrophotometry and GC-MS were used for sterol analyses. In vivo virulence was determined in the insect model Galleria mellonella and evaluated by log-rank Mantel-Cox tests. RESULTS: P-1â+âP-2 were susceptible, P-3â+âP-4 fluconazole resistant, P-5 pan-azole resistant, P-6â+âP-7 pan-azole and echinocandin resistant and P-8â+âP-9 MDR. MLST supported genetic relatedness among clinical isolates. P-4 harboured four changes in Erg11 (E266D, G307S, G450E and V488I), increased expression of ERG11 and CDR2 and a change in Tac1 (R688Q). P-5, P-7, P-8 and P-9 had an additional change in Erg11 (A61E), increased expression of CDR1, CDR2 and ERG11 (except for P-7) and a different amino acid change in Tac1 (R673L). Echinocandin-resistant isolates harboured the Fks1 S645P alteration. Polyene-resistant P-8â+âP-9 lacked ergosterol and harboured a frameshift mutation in ERG2 (F105SfsX23). Virulence was attenuated (but equivalent) in the clinical isolates, but higher than in the azole- and echinocandin-resistant unrelated control strain. CONCLUSIONS: C. albicans demonstrates a diverse capacity to adapt to antifungal exposure. Potentially novel resistance-inducing mutations in TAC1, ERG11 and ERG2 require independent validation.
Assuntos
Anfotericina B/farmacologia , Antifúngicos/farmacologia , Azóis/farmacologia , Candida albicans/efeitos dos fármacos , Candidíase/tratamento farmacológico , Farmacorresistência Fúngica Múltipla , Equinocandinas/farmacologia , Idoso , Animais , Candida albicans/classificação , Candida albicans/genética , Candidíase/microbiologia , DNA Fúngico/química , DNA Fúngico/genética , Genótipo , Humanos , Lepidópteros/microbiologia , Masculino , Testes de Sensibilidade Microbiana , Tipagem de Sequências Multilocus , Mutação , Análise de Sequência de DNA , Análise de Sobrevida , VirulênciaRESUMO
Trichophyton onychocola is a recently described geophilic dermatophyte that has been isolated from a toenail of Czech patient with a history of onychomycosis due to T. rubrum and clinical suspicion of relapse. In this study, we report a similar case from Denmark in an otherwise healthy 56-year-old man. The patient had a history of great toenail infection caused by T. rubrum in 2004 and presented with suspected relapse in 2011 and 2013. Trichophyton onychocola was the only microbial agent isolated at the second visit in 2013 and the identification was confirmed by DNA sequencing. Direct microscopic nail examination was positive for hyphae, however the etiological significance of T. onychocola was not supported by repeated isolation of the fungus. This new species may be an overlooked geophilic species due to the resemblance to some common species, for example, zoophilic T. interdigitale or some species of geophilic dermatophytes. We included differential diagnosis with phenotypically similar species; however, it is recommended that molecular methods are used for correct identification. The MAT locus of Danish strain was of opposite mating type than in the previously isolated Czech strain and the two isolates were successfully mated. The mating experiments with related heterothallic species T. thuringiense and Arthroderma melis were negative. The sexual state showed all typical signs of arthroderma-morph and is described by using optical as well as scanning electron microscopy. The sexual state was induced on a set of agar media, however low cultivation temperature and the presence of keratin source were crucial for the success rather than formulation of medium.
Assuntos
Divisão Celular , Troca Genética , Onicomicose/diagnóstico , Onicomicose/microbiologia , Trichophyton/genética , Trichophyton/fisiologia , Meios de Cultura/química , DNA Fúngico/química , DNA Fúngico/genética , Dinamarca , Genes Fúngicos Tipo Acasalamento , Humanos , Masculino , Microscopia , Pessoa de Meia-Idade , Dados de Sequência Molecular , Unhas/microbiologia , Unhas/patologia , Análise de Sequência de DNA , Trichophyton/isolamento & purificaçãoRESUMO
Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥ 5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.
Assuntos
Antifúngicos/farmacologia , Candida/genética , Candidíase/microbiologia , Equinocandinas/farmacologia , Glucosiltransferases/genética , Substituição de Aminoácidos , Anidulafungina , Antifúngicos/uso terapêutico , Candida/efeitos dos fármacos , Candidíase/complicações , Candidíase/tratamento farmacológico , Infarto Cerebral/complicações , Equinocandinas/uso terapêutico , Evolução Fatal , Feminino , Proteínas Fúngicas/genética , Humanos , Linfoma Difuso de Grandes Células B/complicações , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Mutação de Sentido Incorreto , Análise de Sequência de DNA , Especificidade da Espécie , Falha de TratamentoRESUMO
Three Candida tropicalis isolates were obtained from a patient with acute lymphoblastic leukemia. The first isolate was susceptible to all drug classes, while isolates 2 and 3, obtained after 8 and 8.5 weeks of caspofungin treatment, respectively, were resistant to the three echinocandins. Multilocus sequence genotyping suggested a clonal relation among all isolates. FKS1 sequencing revealed a stepwise development of a heterozygous and finally a homozygous mutation, leading to S80S/P and S80P amino acid substitutions.
Assuntos
Substituição de Aminoácidos/genética , Candida tropicalis/genética , Candidíase/tratamento farmacológico , Proteínas Fúngicas/genética , Glucosiltransferases/genética , Homozigoto , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Antifúngicos/farmacologia , Antifúngicos/uso terapêutico , Candida tropicalis/efeitos dos fármacos , Candida tropicalis/crescimento & desenvolvimento , Candidíase/complicações , Candidíase/microbiologia , Células Clonais , Farmacorresistência Fúngica/genética , Equinocandinas/farmacologia , Equinocandinas/uso terapêutico , Humanos , Testes de Sensibilidade Microbiana , Tipagem de Sequências Multilocus , Mutação , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Leucemia-Linfoma Linfoblástico de Células Precursoras/microbiologia , Prolina/genética , Análise de Sequência de DNA , Serina/genéticaRESUMO
We recently observed that the micafungin MICs for some Candida glabrata fks hot spot mutant isolates are less elevated than those for the other echinocandins, suggesting that the efficacy of micafungin may be differentially dependent on such mutations. Three clinical C. glabrata isolates with or without (S3) fks hot spot mutations R83 (Fks2p-S663F) and RR24 (Fks1p-S629P) and low, medium, and high echinocandin MICs, respectively, were evaluated to assess the in vivo efficacy in an immunocompetent mouse model using three doses of each echinocandin. Drug concentrations were determined in plasma and kidneys by high-performance liquid chromatography (HPLC). A pharmacokinetic-pharmacodynamic mathematical model was used to define the area under the concentration-time curve (AUC) that produced half- and near-maximal activity. Micafungin was equally efficacious against the S3 and R83 isolates. The estimates for the AUCs of each echinocandin that induced half-maximal effect (E(50)s) were 194.2 and 53.99 mg · h/liter, respectively. In contrast, the maximum effect (E(max)) for caspofungin was higher against S3 than R83, but the estimates for E(50) were similar (187.1 and 203.5 mg · h/liter, respectively). Anidulafungin failed to induce a ≥1-log reduction for any of the isolates (AUC range, 139 to 557 mg · h/liter). None of the echinocandins were efficacious in mice challenged with the RR24 isolate despite lower virulence (reduced maximal growth, prolonged lag phase, and lower kidney burden). The AUC associated with half-maximal effect was higher than the average human exposure for all drug-dose-bug combinations except micafungin and the R83 isolate. In conclusion, differences in micafungin MICs are associated with differential antifungal activities in the animal model. This study may have implications for clinical practice and echinocandin breakpoint determination, and further studies are warranted.
Assuntos
Antifúngicos/farmacologia , Candida glabrata/efeitos dos fármacos , Farmacorresistência Fúngica/genética , Equinocandinas/farmacologia , Glucosiltransferases/genética , Lipopeptídeos/farmacologia , Anidulafungina , Animais , Antifúngicos/sangue , Antifúngicos/farmacocinética , Área Sob a Curva , Disponibilidade Biológica , Candida glabrata/genética , Candida glabrata/isolamento & purificação , Candidíase/sangue , Candidíase/tratamento farmacológico , Candidíase/microbiologia , Caspofungina , Cromatografia Líquida de Alta Pressão , Modelos Animais de Doenças , Equinocandinas/sangue , Equinocandinas/farmacocinética , Genes Fúngicos , Glucosiltransferases/metabolismo , Humanos , Rim/efeitos dos fármacos , Rim/metabolismo , Rim/microbiologia , Lipopeptídeos/sangue , Lipopeptídeos/farmacocinética , Micafungina , Camundongos , Testes de Sensibilidade Microbiana , MutaçãoRESUMO
The susceptibilities of Candida isolates to the echinocandins anidulafungin, caspofungin, and micafungin were determined by using the recently revised CLSI breakpoints and Etest on 238 clinical bloodstream Candida isolates collected between September 2005 and August 2006. The isolates represent approximately 95% of all non-albicans Candida bloodstream infections and one-third of Candida albicans bloodstream infections during this 1-year period in Sweden. The collection included 81 C. albicans, 81 C. glabrata, 36 C. parapsilosis, 14 C. dubliniensis, 8 C. tropicalis, 8 C. lusitaniae, 5 C. krusei, 2 C. guilliermondii and 2 C. inconspicua isolates as well as 1 C. pelliculosa isolate. The MICs were largely consistent with the global epidemiology of bloodstream Candida isolates. All C. albicans and C. glabrata isolates were susceptible to all 3 echinocandins (MIC ≤ 0.016 µg/ml in all instances). Resistance (MIC ≥ 8 µg/ml) to anidulafungin alone was observed for 4 (11.1%) C. parapsilosis isolates and for 1/2 C. guilliermondii isolates. Intermediate susceptibility to caspofungin alone was observed for 2/5 C. krusei isolates. One of the eight C. tropicalis isolates was classified as being intermediately susceptible to micafungin (MIC, 0.5 µg/ml) and as being resistant to anidulafungin and caspofungin (MIC ≥ 1 µg/ml). This isolate harbored a heterozygous FKS1 hot spot mutation (S80P) known to confer echinocandin resistance. This first study to apply the revised CLSI breakpoints for Etest endpoints showed that the breakpoints worked successfully in detecting an isolate with a hot spot mutation. Acquired echinocandin resistance is rare in Sweden. Echinocandin MICs against C. parapsilosis and C. guilliermondii were lowest for micafungin.
Assuntos
Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Candidíase/microbiologia , Equinocandinas/farmacologia , Fungemia/microbiologia , Lipopeptídeos/farmacologia , Anidulafungina , Candida/isolamento & purificação , Caspofungina , Proteínas Fúngicas/genética , Glucosiltransferases/genética , Humanos , Micafungina , Testes de Sensibilidade Microbiana , Mutação de Sentido Incorreto , SuéciaRESUMO
Respiratory tract colonization by molds in patients with cystic fibrosis (CF) were analyzed, with particular focus on the frequency, genotype, and underlying mechanism of azole resistance among Aspergillus fumigatus isolates. Clinical and demographic data were also analyzed. A total of 3,336 respiratory samples from 287 CF patients were collected during two 6-month periods in 2007 and 2009. Azole resistance was detected using an itraconazole screening agar (4 mg/liter) and the EUCAST method. cyp51A gene sequencing and microsatellite genotyping were performed for isolates from patients harboring azole-resistant A. fumigatus. Aspergillus spp. were present in 145 patients (51%), of whom 63 (22%) were persistently colonized. Twelve patients (4%) harbored other molds. Persistently colonized patients were older, provided more samples, and more often had a chronic bacterial infection. Six of 133 patients (4.5%) harbored azole-nonsusceptible or -resistant A. fumigatus isolates, and five of those six patients had isolates with Cyp51A alterations (M220K, tandem repeat [TR]/L98H, TR/L98H-S297T-F495I, M220I-V101F, and Y431C). All six patients were previously exposed to azoles. Genotyping revealed (i) microevolution for A. fumigatus isolates received consecutively over the 2-year period, (ii) susceptible and resistant isolates (not involving TR/L98H isolates) with identical or very closely related genotypes (two patients), and (iii) two related susceptible isolates and a third unrelated resistant isolate with a unique genotype and the TR/L98H resistance combination (one patient). Aspergilli were frequently found in Danish CF patients, with 4.5% of the A. fumigatus isolates being azole nonsusceptible or resistant. Genotyping suggested selection of resistance in the patient as well as resistance being achieved in the environment.
Assuntos
Antifúngicos/farmacologia , Aspergillus fumigatus/efeitos dos fármacos , Azóis/farmacologia , Fibrose Cística/complicações , Farmacorresistência Fúngica , Fungos/isolamento & purificação , Pneumopatias Fúngicas/epidemiologia , Adolescente , Adulto , Criança , Pré-Escolar , Sistema Enzimático do Citocromo P-450/genética , Feminino , Proteínas Fúngicas/genética , Fungos/classificação , Genótipo , Humanos , Lactente , Pneumopatias Fúngicas/microbiologia , Masculino , Testes de Sensibilidade Microbiana , Repetições de Microssatélites , Pessoa de Meia-Idade , Mutação de Sentido Incorreto , Técnicas de Tipagem Micológica , Prevalência , Adulto JovemRESUMO
Besides inherent differences in in vitro susceptibilities, clinically-relevant yeast species may acquire resistance upon exposure to most antifungal drugs used in the clinic. In recent years, major fundamental research studies have been conducted to improve our understanding of the molecular basis of antifungal resistance. This topic is of major interest as antifungal resistance in yeast is clearly evolving and is correlated with clinical failure. This minireview is an overview of the most recent findings about key molecular mechanisms evolving in human pathogenic yeasts, particularly Candida spp., in the context of antifungal drug resistance. Also included are the methods currently available for in vitro antifungal susceptibility testing and for molecular detection of mutations associated with resistance. Finally, the genetic drivers of antifungal resistance are discussed in light of the spectra of multidrug resistance as observed in Candida glabrata.
Assuntos
Candida/efeitos dos fármacos , Candida/genética , Farmacorresistência Fúngica , Genes Fúngicos , Antifúngicos/farmacologia , Humanos , Testes de Sensibilidade Microbiana/métodos , MutaçãoRESUMO
Antifungal drug resistance is a multifaceted clinical challenge, and when present, a primary cause of treatment failure in patients with severe fungal infections. Changing epidemiology, increasing resistance rates and a narrow antifungal armamentarium may further underline the required attention on resistance particularly within the most prevalent invasive fungal infections caused by Candida yeasts and Aspergillus moulds. In Denmark, the resistance epidemiology remains to be fully elucidated. This thesis sought to address this demand as well as provide insight into the landscape of underlying molecular resistance mechanisms. Paper I and II both contributed to the understanding of FKS (ß-glucan synthase) mediated echinocandin resistance in Candida species. Paper I covered a unique stepwise acquisition of a homozygous mutation in FKS1 of Candida tropicalis leading to an amino acid change corresponding to a well-known S645P in Candida albicans. Paper II presented a failure case due to Candida krusei displaying high-level echinocandin resistance likely attributable to an acquired D662Y amino acid substitution in FKS1. Intrinsic differences in FKS1 among Candida species may explain why the level of resistance both depends on the mutation as well as the species and cannot be easily translated to the level of clinical resistance. Intrinsic fluconazole resistance in C. krusei further substantiated the clinical implications of acquired echinocandin resistance. Paper III presented a rare multidrug resistance case in a series of isogenic C. albicans isolates, almost covering the entire spectrum of known resistance mechanisms in Candida and involved the proposal of novel resistance mutations. An A61E change in ERG11 was potentially involved in reduced susceptibility to long-structured azoles. Increased expression levels of azole efflux pumps were probably accredited to novel gain-of-function variants in the transcription factor TAC1 (R688Q and R673L). Echinocandin resistance was induced by the well-known S645P variant of FKS1 and polyene resistance was likely inflicted by a frameshift mutation in ERG2 leading to loss of function of the encoded protein and subsequent ergosterol depletion. The number of acquired resistance cases is increasing in our settings and Paper IV sought to illuminate whether antifungal resistance is overlooked in the current fungaemia programme. This involved the acquisition of post-treatment oral isolates from 193 candidaemia patients among which 114 received azoles (primarily fluconazole) and 85 received an echinocandin (and some both). Azole-exposed patients carried a significantly higher proportion of species less susceptible to fluconazole (primarily Candida glabrata) among colonising Candida compared to baseline blood isolates (p<0.001). A similar trend was seen for echinocandin-treated patients although not statistically significant. Interestingly, there was a high frequency of acquired resistance, 29.4% to fluconazole and 21.6% to echinocandins, among colonising C. glabrata isolates post treatment. These figures were both significantly higher compared to baseline blood isolates as well as oral isolates from patients with no or minimal exposure to either drug class. In contrast, acquired resistance among C. albicans oral isolates was rare (<5). Thus, the oral cavity may be an unrecognized reservoir of resistant Candida species, especially C. glabrata following azole or echinocandin treatment. This underlines the care of which therapeutic stewardship must be taken both for antifungal naïve patients, to avoid resistance development, as well as for patients previously exposed to antifungals. Paper V presented four fatal cases of invasive aspergillosis involving azole resistant Aspergillus fumigatus harbouring resistance mechanisms (TR34/L98H and TR46/Y121F/T289A), which are thought to derive from environmental fungicide use. The clinical concern is evident because the route of infection is through inhalation of potentially azole resistant spores. Still, recent environmental surveys were unable to detect azole resistant A. fumigatus in numerous soil samples but seasonal variations could be one explanation for this paradox. Paper VI was a retrospective laboratory-based study and aimed to elucidate the prevalence of azole resistance in A. fumigatus isolates from 2010-2014 in Denmark. This study also sought to uncover the underlying resistance mechanisms, primarily attributable to CYP51A mutations, and finally to assess the accumulated genotyping data. Among 1,162 A. fumigatus isolates, 94.5% were screened for azole resistance and a significant increasing trend was observed for the number of azole-resistant isolates to approximately 6% in 2014 (p<0.001) and 4% in corresponding patients (p<0.05). The underlying resistance mutations were diverse but still dominated by the TR34/L98H resistance mechanism responsible for >50% of all our azole-resistant isolates. The genotyping data of resistant and a selection of susceptible A. fumigatus showed high identity to foreign isolates (>15%). This could argue for the hypothesis on clonal expansion, which has previously been suggested for TR34/L98H clones in the Netherlands and India, but could also indicate an insufficient discriminatory power of such analysis. Still, a proposed A. fumigatus outbreak in a haematology ward was unresolved since no genetically identical isolates were recovered from patients and air samples, illustrating the ubiquitous nature of this organism. Overall, the main concerns are a changing Candida epidemiology towards species less susceptible to fluconazole combined with the rapid acquisition of echinocandin resistance, especially among C. glabrata isolates. For A. fumigatus, the concern is the emergence of azole resistant strains in the environment, displaying cross-resistance to clinical azoles, and thus posing unforeseen clinical challenges in the management of invasive aspergillosis. Collectively, these findings call for an increased awareness especially at clinical microbiology laboratories, which ideally would lead to susceptibility testing of all clinically relevant isolates by reference or validated methods. Moreover, novel diagnostic approaches for non-culturable pathogens are warranted and especially DNA-based detection by PCR may serve as a solid complimentary tool for improved diagnostics of invasive fungal infections.
Assuntos
Antifúngicos/farmacologia , Farmacorresistência Fúngica , Fungos/efeitos dos fármacos , Micoses/tratamento farmacológico , Dinamarca/epidemiologia , Humanos , Incidência , Testes de Sensibilidade Microbiana , Micoses/epidemiologiaRESUMO
We report Aspergillus delacroxii (formerly Aspergillus nidulans var. echinulatus) causing recurrent prosthetic valve endocarditis. The fungus was the sole agent detected during replacement of a mechanical aortic valve conduit due to abscess formation. Despite extensive surgery and anti-fungal treatment, the patient had a cerebral hemorrhage 4 months post-surgery prompting a diagnosis of recurrent prosthetic valve endocarditis and fungemia.